Russia announced its second coronavirus vaccine was 94% effective and works against all strains

The second russian coronavirus vaccine, EpiVacCorona, he has one 94% effective in the elderly and provides immunity for at least a year, said this Wednesday Alexandr semionov, director of the National Center for Research in Virology and Biotechnology Vector, manufacturer of the preparation.

“The use of the vaccine generates effective antibodies in 94% of cases and in the rest it protects against a serious development of the infection”Semyonov said in statements to the radio station FM News.

Rospotrebnadzor, the Russian consumer agency, which acts as a health regulator, clarified that this percentage of effectiveness of EpiVaCorona was established in clinical trials with people over 60.

“It works against all known variants, against the British, South Americans and South Africans”Semyonov assured.

The vaccine, he added, can be quickly modified for use against new strains that appear from the coronavirus responsible for the COVID-19 disease.

The scientist assured that the EpiVacCorona provides immunity against the coronavirus for one year and “theoretically it should be two years”.

“At the moment, we just dare not give an official forecast because little time has passed. The first vaccinated were vaccinated very recently “explained Semiónov, who recalled that the EpiVacVCorona is in the third phase of clinical trials.

The preparation, the second vaccine registered in Russia after Sputnik V, is administered in two doses and generates the required amount of antibody 42 days after the first injection.

The director of Véktor indicated that this month there will be 1.5 million doses of EpiVacCorona, and that in May and June production will increase at 3 and 5 million doses, respectively.

Russia today accumulates more than 4.6 million positive for COVID-19 and 101,480 deaths disease-related.

(With information from EFE)

KEEP READING: